This week in the 2015 Conference Coverage section of the CLL Society website, we have posted an interview from ASH 2015 with Dr. Jeff Jones from Ohio State University. We discussed the data for patients with relapsed/refractory CLL on combining the BCL-2 ( B-cell lymphoma-2) inhibitor venetoclax with the antibody obinutuzumab, the ongoing European trials and a new study that adds ibrutinib to that mix. You can see a summary and view our interview here.
This is an exciting week for the CLL Society as we mark the first year since we launched our website on Thursday. March 31st. In that time we have had over 170,000 page views and we continue to grow as 46% of our readers are new to the site. We are so thankful for the support and positive feedback we have received during this time and hope we can continue to fulfill our mission to meet the unmet needs of CLL patients and their caregivers.
The other excitement for the week is that we will launch the first 2016 issue of The CLL Tribune on Thursday, in recognition of completing our first year.
We are also forming 2 new patient and caregiver support meetings: Charlotte, NC and Tampa FL.
- If you live in Charlotte, NC and are interested, please complete the online survey to indicate your preferences for days and times.
- If you live in Tampa, FL and are interested, please complete the online survey to indicate your preferences for days and times. We look forward to getting started.
LAST CALL: This Saturday, April 2nd at 7:30 AM in Manhattan Beach, California: The Lymphoma Workshop: Understanding Lymphoma Basics and Current Treatment Options will be hosted by the Lymphoma Research Foundation. It will be held at the Manhattan Beach Marriott from 7:30 AM to 3:30 PM. You can find out more information and register here. The CLL Society will have a table there. Please come by and say Hello!
In the meantime….
We are all in this together.
Brian Koffman, MD
Volunteer Medical Director of the CLL Society